Images List Premium Download Classic

Pharmaceutically Acceptable Salts

Pharmaceutically Acceptable Salts-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
April 12, 2018 - N°20180099967

And pharmaceutically acceptable salts thereof, wherein r1, r2 and r3 are as defined herein. The present invention also relates to compositions comprising at least one fused tricyclic heterocyclic compound, and methods of using the fused tricyclic heterocyclic compounds for treating or preventing hiv infection in a subject.
Naphthyridine compounds, medical combinations and use thereof
Wuhan Novaffey Science & Technology Co., Ltd.
April 12, 2018 - N°20180099962

This invention involves the field of biomedicine, and reveals naphthyridine compounds, medical combinations and use thereof. The naphthyridine compounds has the structure as shown by formula (i), or its stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or their prodrugs. The naphthyridine compounds of this invention has anti-tumor efficacy significantly superior to that of prior art. ...
Quinazoline derivatives as vegf inhibitors
Genzyme Corporation
April 12, 2018 - N°20180099946

The invention relates to quinazoline derivatives of formula (i), wherein m is an integer from 1 to 3; r1 represents halogeno or c1-3alkyl; x1 represents —o—; r2 is selected from one of the following three groups: 1) c1-5alkylr3 (wherein r3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, c1-4 alkyl, ...
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Prmt5 inhibitors and uses thereof
Epizyme, Inc.
April 12, 2018 - N°20180098987

Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity. Methods of using the compounds for treating prmt5-mediated disorders are also described.
Indole derivatives
Richter Gedeon Nyrt.
April 05, 2018 - N°20180093989

The present invention relates to compounds of the general form (i). The present invention relates to new substituted diazepino-indole derivatives of the general formula (i), and to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising such compounds, to new intermediate thereof as well as to the use of such compounds in treatment or prevention of disorders associated ...
1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
April 05, 2018 - N°20180093974

And pharmaceutically acceptable salts thereof, wherein a, ra, r1, r2, r3, r4, r6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Benzo[b]thiophene compounds as sting agonists
Merck Sharp & Dohme Corp.
April 05, 2018 - N°20180093964

Compounds of general formula (ia), compounds of general formula (ia′), compounds of general formula (ib), compounds of general formula (ib′), compounds of general formula (i), compounds of general formula (i′), and their pharmaceutically acceptable salts, wherein r1, r2, r3, r4, r5, r6, r8, r9, x1, x2, and x3 are defined herein, that may be useful as inductors ...
Substituted phthalazines
April 05, 2018 - N°20180093956

Wherein r1, r2, r3, r4, r5, and r6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by suv420h1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (i).
Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of ...
Sumitomo Dainippon Pharma Co., Ltd.
April 05, 2018 - N°20180092909

Dosage regimens for at least one compound chosen from lurasidone and pharmaceutically acceptable salts, solvates, clathrates, and stereoisomers thereof are disclosed as are kits and methods for treatment and/or prevention of at least one cns disorder such as, for example, mixed depression and bipolar disorder, and management of at least one cns disorder, such as improving quality of life ...
Preparation of deoxycholic acid
Bionice, S.l.u.
March 29, 2018 - N°20180086786

The present invention relates to new and improved processes for the preparation of deoxycholic acid (dca) and pharmaceutically acceptable salts thereof, as well as to dca and pharmaceutically acceptable salts thereof, the carbon atoms of which are derived solely from plant sources.
Phosphatidylinositol 3-kinase inhibitors
March 29, 2018 - N°20180086768

Or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, r1, r2, r3, r4, r5, and r6 are as described herein.
Cxcr7 antagonists
March 29, 2018 - N°20180086766

Or pharmaceutically acceptable salts, hydrates or n-oxides thereof are provided and are useful for binding to cxcr7, and treating diseases that are dependent, at least in part, on cxcr7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
Tgf-ß inhibitors
Rigel Pharmaceuticals, Inc.
March 29, 2018 - N°20180086764

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and n-oxides thereof (and solvates and hydrates thereof), wherein a, x, z, m, p, and r2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or ...
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Triazolopyridine compounds and methods of use thereof
Genentech, Inc.
March 29, 2018 - N°20180086757

Provided are triazolopyridine compounds that are inhibitors of jak kinase, such as jak1, compositions containing these compounds and methods for treating diseases mediated by a jak kinase. In particular, provided are compounds of formula (i), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where r1a, r1b, r1c, r2, r3, r4 and r5 are defined herein, pharmaceutical ...
Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
Concert Pharmaceuticals, Inc.
March 29, 2018 - N°20180086743

This invention relates to novel inhibitors of udp-glucose: n-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of udp-glucose: n-acyl-sphingosine glucosyltransferase.
Indazolones as modulators of tnf signaling
Abbvie Inc.
March 29, 2018 - N°20180086737

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.
Flavagline derivatives
Pierre Fabre Medicament
March 29, 2018 - N°20180086729

The invention relates to compounds of the following general formula (i) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to ...
Phosphatidylinositol 3-kinase inhibitors
March 29, 2018 - N°20180086719

Or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, r1, r2, r3, r4, and r6 are as described herein.
Deuterated cftr potentiators
March 29, 2018 - N°20180086711

And pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a cftr potentiator.
Tetrahydropyridine derivatives and their use as antibacterial agents
Dong-a St Co., Ltd.
March 29, 2018 - N°20180086709

The present disclosure relates to a novel tetrahydropyridine derivative compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, methods for preparing the compounds, methods for inhibiting udp-3-o—(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylase (lpxc), methods for treating gram-negative bacterial infections, the use of the compounds for the preparation of therapeutic medicaments for treating gram-negative bacterial infections, and pharmaceutical compositions ...
Disubstituted piperidine derivatives as butyrylcholinesterase inhibitors for use in the treatment of alzheimer
Univerza V Ljubljani
March 29, 2018 - N°20180086707

This invention relates to new inhibitors of butyrylcholinesterase with general formulas i and ii, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the form of pharmaceutically acceptable salts. The present invention relates to the use of these inhibitors for the treatment of alzheimer's disease and other ...
Loading